BR0116803A - Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase - Google Patents

Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase

Info

Publication number
BR0116803A
BR0116803A BR0116803-7A BR0116803A BR0116803A BR 0116803 A BR0116803 A BR 0116803A BR 0116803 A BR0116803 A BR 0116803A BR 0116803 A BR0116803 A BR 0116803A
Authority
BR
Brazil
Prior art keywords
fusion proteins
bifunctional
bifunctional fusion
glucocerebrosidase activity
activity
Prior art date
Application number
BR0116803-7A
Other languages
English (en)
Inventor
Silke Schumacher
Stephen Gillies
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0116803A publication Critical patent/BR0116803A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"PROTEìNAS DE FUSãO BIFUNCIONAIS COM ATIVIDADE DE GLICOCEREBROSIDASE". A presente invenção refere-se às novas proteínas de fusão bifuncionais de glicocerebrosidase, que consistem essencialmente em uma molécula de imunoglobulina (lg) e uma proteína tendo a atividade biológica de glicocerebrosidase, para terapia de substituição de enzima e/ou aumento do metabolismo de glicolipídio pela administração de proteínas de fusão bifuncionais usando uma terapia baseada no tratamento de distúrbios de armazenagem de glicolipídio tais como doenças de Gaucher, de Fabry e TaySachs.
BR0116803-7A 2001-01-18 2001-12-27 Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase BR0116803A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101056 2001-01-18
PCT/EP2001/015328 WO2002057435A2 (en) 2001-01-18 2001-12-27 Bifunctional fusion proteins with glucocerebrosidase activity

Publications (1)

Publication Number Publication Date
BR0116803A true BR0116803A (pt) 2004-02-17

Family

ID=8176235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116803-7A BR0116803A (pt) 2001-01-18 2001-12-27 Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase

Country Status (13)

Country Link
US (1) US20040043457A1 (pt)
EP (1) EP1392826A2 (pt)
JP (1) JP2004525621A (pt)
KR (1) KR20030067755A (pt)
CN (1) CN1630720A (pt)
BR (1) BR0116803A (pt)
CA (1) CA2435037A1 (pt)
HU (1) HUP0401300A3 (pt)
MX (1) MXPA03006294A (pt)
NO (1) NO20033247D0 (pt)
PL (1) PL362394A1 (pt)
WO (1) WO2002057435A2 (pt)
ZA (1) ZA200306333B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CN1235911C (zh) * 1999-08-09 2006-01-11 利思进药品公司 多细胞因子－抗体复合物
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA03009924A (es) * 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
ES2381025T3 (es) * 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
CN1902222A (zh) * 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
DK1706428T3 (da) 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
WO2007012188A1 (en) * 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007076933A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
ES2426468T3 (es) 2005-12-30 2013-10-23 Merck Patent Gmbh Anticuerpos anti-CD19 con inmunogenicidad reducida
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
CA2759333A1 (en) * 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
PE20121337A1 (es) * 2009-11-27 2012-10-12 Genzyme Corp Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
WO2011107992A2 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
PL3272861T3 (pl) 2011-01-20 2020-07-13 Protalix Ltd. Kompozycje alfa- galaktozydazy
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106456714A (zh) * 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd A new medical fusion protein with an enzyme and its uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6475486B1 (en) * 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU5065198A (en) * 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
WO1998046257A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
IL151024A0 (en) * 2000-02-15 2003-02-12 Genzyme Corp Conjugates of a biopolymer and a therapeutic agent
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline

Also Published As

Publication number Publication date
MXPA03006294A (es) 2003-09-16
EP1392826A2 (en) 2004-03-03
NO20033247L (no) 2003-07-17
KR20030067755A (ko) 2003-08-14
PL362394A1 (en) 2004-11-02
JP2004525621A (ja) 2004-08-26
NO20033247D0 (no) 2003-07-17
CA2435037A1 (en) 2002-07-25
WO2002057435A2 (en) 2002-07-25
WO2002057435A3 (en) 2003-12-24
HUP0401300A2 (hu) 2004-09-28
US20040043457A1 (en) 2004-03-04
CN1630720A (zh) 2005-06-22
HUP0401300A3 (en) 2005-06-28
ZA200306333B (en) 2004-11-17

Similar Documents

Publication Publication Date Title
BR0116803A (pt) Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
EP1136561A3 (en) Targeting gene therapy
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
BR0312276A (pt) Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
BR0007840A (pt) Proteìnas de fusão her-2/neu
BR0016126A (pt) Agonistas totais ou parciais de a1 derivados n6 heterocìclicos 5'-tio substituìdos de adenosina
BR9714513A (pt) Genes que codificam para aminoácido-deacetilases com especificidade para n-acetil-l-fosfinotricina, seu isolamento e emprego
BR9816013A (pt) Proteìna de ligação de interleucina-18
BR0316923A (pt) Polipeptìdeo mitoneet de membranas mitocondriais, seus moduladores e métodos para utilização do mesmo
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
BR0009805A (pt) Mutações de enos úteis para terapia genética e rastreamento terapêutico
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
IT1270618B (it) Proteine ad attivita' antitumorale
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
BR9810452A (pt) Nova combinação de medicamentos contra asma
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
MX9605278A (es) Procedimiento para la inactivacion de virus en proteinas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A E 6A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1964 DE 26/08/2008 POR TER SIDO APRESENTADO O PROTOCOLO DE ESCLARECIMENTO NO 420805724230 DE 18/09/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.